AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company with its global headquarters in Cambridge, England. It focuses on the discovery, development, manufacture, and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca also has a significant presence in rare diseases following its acquisition of Alexion. The company is driven by science and innovation to deliver life-changing medicines to patients worldwide.
Serves as the global corporate headquarters and a strategic R&D hub, driving innovation and global operations.
The Discovery Centre (DISC), a state-of-the-art facility with open-plan laboratories designed to foster collaboration. Features advanced robotics, high-throughput screening, and sustainable design elements like ground source heat pumps and green roofs.
A science-led, innovative, and collaborative environment. The Cambridge HQ fosters interaction with the vibrant Cambridge life sciences ecosystem, encouraging a culture of continuous learning and patient-centric research.
The Cambridge HQ centralizes much of AstraZeneca's UK-based R&D, enhancing collaboration and accelerating drug discovery. Its location within the Cambridge Biomedical Campus facilitates partnerships with leading academic and research institutions.
AstraZeneca has a significant global presence, operating in over 100 countries. Its functions are supported globally through strategic R&D centers in the UK (Cambridge), USA (Gaithersburg, MD), and Sweden (Gothenburg). The company also has numerous manufacturing sites strategically located across the world and commercial operations spanning Europe, the Americas, Asia, Africa, and Australia. This extensive network supports the discovery, development, manufacturing, and commercialization of medicines worldwide.
1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge
Cambridgeshire
United Kingdom
Address: One MedImmune Way, Gaithersburg, MD 20878, USA
Serves as a critical hub for AstraZeneca's research and clinical development in North America, leveraging the biotech ecosystem in the Washington D.C. / Maryland region.
Address: Pepparedsleden 1, 431 83 Mölndal, Sweden
Key research and development site in Europe, contributing significantly to AstraZeneca's pipeline and fostering collaboration within the Nordic life science community.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AstraZeneca' leadership includes:
AstraZeneca has been backed by several prominent investors over the years, including:
Over the past year, AstraZeneca has seen key leadership transitions, notably in its R&D division with the retirement of Sir Mene Pangalos and appointment of Sharon Barr. The company also announced a new Chair Designate for the Board and saw the retirement of its Chief Strategy Officer.
Discover the tools AstraZeneca uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AstraZeneca commonly uses the 'firstname.lastname' email format. This is a standard and widely adopted pattern within the company for professional communication.
firstname.lastname@astrazeneca.com
Format
jane.doe@astrazeneca.com
Example
95%
Success rate
AstraZeneca Press Release • May 2, 2024
AstraZeneca announced its financial results for the first quarter of 2024, reporting a 19% increase in total revenue at constant exchange rates. Growth was driven by strong performance across its oncology and biopharmaceuticals portfolio, including its rare disease medicines....more
AstraZeneca Press Release • February 16, 2024
AstraZeneca's TAGRISSO (osimertinib) in combination with chemotherapy was approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This approval is based on the FLAURA2 Phase III trial results....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AstraZeneca, are just a search away.